Joachim Widder
Vienna General Hospital · 239 works · 7,106 citations · h-index 36
Top works
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
- Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach
- Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study
- Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement
- Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
- Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial
- Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer
- Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy?
- Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
- The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine
- Micro- and Nanoplastics Breach the Blood–Brain Barrier (BBB): Biomolecular Corona’s Role Revealed
- Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?
- Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases
- Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC
- Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
- Survival and Quality of Life After Stereotactic or 3D-Conformal Radiotherapy for Inoperable Early-Stage Lung Cancer
- Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control
- Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases
- Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial